Flebogamma DIF: payments to doctors
Payments that named Flebogamma DIF as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $177K
- Providers
- 28
- Transactions
- 180
- Average per transaction
- $985
The per-transaction average — $985 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 28 providers the average total is $6,330, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Grifols Shared Services North America, Inc. | $86,477 | 48.8% |
| Grifols Biologicals LLC | $76,202 | 43.0% |
| Grifols, S.A. | $12,086 | 6.8% |
| Grifols Therapeutics LLC | $2,473 | 1.4% |